ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,028.20
      0.20%
      US Tech 100
      16,924.32
      0.38%
      Dow Jones
      37,999.66
      0.25%
      Brent Oil
      83.28
      -0.31%
      Bitcoin
      58,615.99
      0.65%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. ADC Therapeutics SA (ADCT)

      7. ADC Therapeutics SA (ADCT) News

      ADCT

      ADC Therapeutics (ADCT)

      ADC Therapeutics SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ADCT
      DateTimeSourceHeadlineSymbolCompany
      05/01/20244:05PMGlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
      05/01/20247:00AMGlobeNewswire Inc.ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024NYSE:ADCTADC Therapeutics SA
      04/04/20247:00AMGlobeNewswire Inc.ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaNYSE:ADCTADC Therapeutics SA
      04/03/20247:00AMGlobeNewswire Inc.ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024NYSE:ADCTADC Therapeutics SA
      04/01/20244:05PMGlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
      03/13/20247:03AMIH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNYSE:ADCTADC Therapeutics SA
      03/13/20247:00AMGlobeNewswire Inc.ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
      03/06/20247:15AMGlobeNewswire Inc.ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitNYSE:ADCTADC Therapeutics SA
      03/06/20247:00AMGlobeNewswire Inc.ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024NYSE:ADCTADC Therapeutics SA
      03/05/20245:45PMGlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingNYSE:ADCTADC Therapeutics SA
      03/05/20249:15AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      02/29/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      02/27/20247:00AMGlobeNewswire Inc.ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:ADCTADC Therapeutics SA
      01/24/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      01/19/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      01/04/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      01/04/20247:15AMGlobeNewswire Inc.ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
      01/04/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
      01/04/20247:00AMGlobeNewswire Inc.ADC Therapeutics Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
      01/02/20248:10PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      01/02/20248:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      01/02/20248:04PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      01/02/20248:00PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      01/02/20247:59PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      01/02/20247:58PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
      12/19/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:ADCTADC Therapeutics SA
      12/18/20234:25PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
      12/12/20235:15AMGlobeNewswire Inc.ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)NYSE:ADCTADC Therapeutics SA
      12/04/20234:57PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
      11/20/20232:40AMPR Newswire (US)Sobi to present new data at ASH 2023 Annual MeetingNYSE:ADCTADC Therapeutics SA
       Showing the most relevant articles for your search:NYSE:ADCT